Conatus Pharmaceuticals Inc. (57) | Business Operations (7)

Browse by Subcategory

Recent Contracts

Collaborative Development and Commercialization Agreement, dated as of October 26, 2020, by and between the Company and Amerimmune LLC (Filed With SEC on October 27, 2020)
Form of Indemnification Agreement, between Histogen Inc. and its officers and directors (Filed With SEC on February 7, 2020)
Settlement, Release and Termination Agreement, dated April 5, 2019, by and among Histogen Inc., PUR Biologics, LLC, Wylde, LLC, Christopher Wiggins and Ryan Fernan (Filed With SEC on February 7, 2020)
Amended and Restated Supply Agreement, dated December 16, 2013, by and between Histogen Inc. and Suneva Medical, Inc (Filed With SEC on February 7, 2020)
Amendment to Option, Collaboration and License Agreement, dated September 30, 2019, by and between Novartis Pharma AG and Conatus (Filed With SEC on October 4, 2019)
Conversion, Termination and Release Agreement, dated August 10, 2016, by and among Histogen Inc., Jonathan Jackson, Lordship Ventures LLC and Lordship Ventures Histogen Holdings... (Filed With SEC on February 7, 2020)
Termination of Stockholder Agreements, dated January 28, 2020, by and among Histogen Inc., Lordship Ventures Histogen Holdings LLC, Pineworld Capital Limited, Gail K. Naughton,... (Filed With SEC on February 7, 2020)